Jane Street
CTMX icon

Jane Street’s CytomX Therapeutics CTMX Stock Holding History

Jane Street’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$318K Buy
+67,600
New +$343K ﹤0.01% 9117
2025
Q4 		– Sell
-12,800
Closed -$40.8K – 11306
2025
Q3 		$40.8K Buy
+12,800
New +$28.8K ﹤0.01% 10399

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street's CTMX Position: Q1 2026 in Review

Jane Street increased its CytomX Therapeutics (CTMX) stake by 64% in Q1 2026, buying an estimated $1.98M and bringing the position to 997,510 shares worth $4.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3621.

Jane Street first reported a position in CTMX in Q2 2020 and has held it in 20 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Jane Street held 997,510 shares of CytomX Therapeutics worth $4.69M as of Q1 2026.
  • Jane Street bought 390,292 CytomX Therapeutics shares in Q1 2026, an estimated $1.98M.
  • CytomX Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3621 holding.
  • Jane Street first reported a position in CytomX Therapeutics in Q2 2020 and has held it in 20 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.